无病生存期作为HR+/HER2-早期乳腺癌总生存期的替代终点:一项相关性分析
该分析基于14项随机对照试验的系统文献综述,评估无病生存期(DFS)作为激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)早期乳腺癌辅助治疗总生存期(OS)替代终点的相关性。结果显示OS与DFS风险比的未加权Spearman相关系数为0.81(加权0.81),加权回归R²为84%,DFS/OS风险比的替代阈值效应为0.82,结论支持DFS作为可靠的替代终点。
要点
- 14项RCT的基座分析显示OS与DFS风险比的未加权Spearman相关系数为0.81(加权0.81)。
- 加权回归中84%的OS变异可由DFS差异解释(R²)。
- DFS/OS风险比的替代阈值效应为0.82。
核心结论
- 这些分析支持DFS作为HR+/HER2-早期乳腺癌辅助治疗试验中OS的可靠替代终点。
- 使用DFS作为替代指标将使HR+/HER2-早期乳腺癌患者更及时地获得新治疗。
研究设计与样本
- 进行了系统文献综述,纳入成人HR+/HER2-早期乳腺癌患者占比≥80%的随机对照试验。
- 纳入的随机对照试验评估了多种全身治疗类别,关键纳入标准包括报告DFS和OS风险比及成熟的OS数据。
- 采用Spearman秩相关和加权线性回归分析评估DFS与OS风险比的相关性。
- 进行了情景分析检验基座分析的稳健性,并使用患者水平数据进行了平行分析。
主要发现
- 基座分析(N=14项随机对照试验)显示OS与DFS之间的未加权Spearman系数为0.81(加权:0.81),加权回归中84%的OS变异可由DFS差异解释(R²)。
- DFS/OS风险比的替代阈值效应为0.82。
- 排除化疗试验的情景分析(n=9项随机对照试验)与基座分析一致。
- 使用FACE试验数据的患者水平分析与基座分析一致。
关键数值与推荐
- 基座分析(N=14项随机对照试验):OS与DFS未加权Spearman系数0.81,加权0.81。
- 基座分析:加权回归R²为84%。
- DFS/OS风险比的替代阈值效应为0.82。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a primary endpoint for early breast cancer (EBC) trials, as follow-up is comparatively shorter. Here, we present an analysis evaluating DFS as a surrogate for OS for adjuvant treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) EBC. METHODS: A systematic literature review which included randomized controlled trials (RCTs) with ≥80% of adult patients with HR+/HER2- EBC was conducted. The RCTs evaluated various systemic therapeutic categories; key inclusion criteria included reporting of DFS and OS hazard ratios (HRs) and mature OS data. Spearman rank correlation and weighted linear regression analyses evaluated DFS and OS HR correlation. A scenario analysis tested base-case analysis robustness, and a parallel analysis using patient-level data was conducted. RESULTS: The base case (N = 14 RCTs) showed an unweighted Spearman coefficient of 0.81 between OS and DFS (weighted: 0.81), with 84% of the variability in OS explained by DFS differences (R2 from weighted regression). The surrogate threshold effect (Burzykowski T, Buyse M. Pharm Stat. 2006;5:173-186) was 0.82 for DFS/OS HR. Scenario analysis (n = 9 RCTs), which excluded chemotherapy trials, and patient-level analysis using FACE trial data were consistent with the base-case analysis. CONCLUSIONS: These analyses support DFS as a reliable surrogate endpoint for OS in adjuvant HR+/HER2- EBC trials. Using DFS as a surrogate measure will permit timelier access to novel treatments for patients with HR+/HER2- EBC.
引用
- Untch M, Pérol D, Mayer EL, et al. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis. Eur J Cancer. 2024. PMID: 38460476. doi:10.1016/j.ejca.2024.113977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。